BioSim™ anti-Pembrolizumab (Keytruda®) (Human) ELISA Kit

Pembrolizumab (Keytruda®) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Pembrolizumab ELISA kit is designed to detect antibody against Pembrolizumab with high specificity and sensitivity in biological matrices.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the qualitative determination of antibody against Pembrolizumab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- qualitative determination of antibody against Pembrolizumab (Keytruda) in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for Qualitative determination of antibody against Pembrolizumab (Keytruda) in serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Pembrolizumab (Keytruda) in human serum and plasma. Cross Reactivity: Pembrolizumab (Keytruda®) infusion camouflages/masks the presence of antibody to Pembrolizumab (ATP) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATP. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Pembrolizumab.